{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:20:30Z","timestamp":1790194830767,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>Current cardiac safety testing focuses on detecting drug\u2010induced QT<jats:sub>C<\/jats:sub> prolongation as a surrogate for risk of Torsade de Pointes. The nonclinical strategy, described in International Conference on Harmonization (ICH) S7B, includes <jats:italic>in vitro<\/jats:italic> assessment of hERG block or ventricular repolarization delay and <jats:italic>in vivo<\/jats:italic> QT prolongation. Several studies have reported predictive values of ICH S7B results for clinical QT<jats:sub>C<\/jats:sub> outcomes for small molecules; none has examined peptides and proteins other than monoclonal antibodies. To address this knowledge gap, information for peptides and proteins submitted to the US Food and Drug Administration (FDA) was collected. Results of hERG assays, ventricular repolarization assays, and <jats:italic>in vivo<\/jats:italic> QT assessment were compared with clinical QT<jats:sub>C<\/jats:sub> study outcomes. The results show that 14% clinical QT<jats:sub>C<\/jats:sub> studies for approved and investigational products failed to exclude 10\u2010ms QT<jats:sub>C<\/jats:sub> prolongation. Clinical QT<jats:sub>C<\/jats:sub> prolongation for these molecules lacked concentration\u2010dependence which is expected for hERG block\u2010mediated mechanism or QT<jats:sub>C<\/jats:sub> prolongation could not be excluded due to characterization in the clinical study. The hERG and ventricular repolarization assays do not identify clinical QT<jats:sub>C<\/jats:sub> prolongation potential for peptides and proteins. Lack of alignment between hERG and ventricular repolarization assay results and clinical QT<jats:sub>C<\/jats:sub> outcomes suggests that the mechanisms of QT<jats:sub>C<\/jats:sub> prolongation by some peptides and proteins are unrelated to direct cardiac ion channel block. Similar to large targeted proteins and monoclonal antibodies, peptides and proteins regardless of size have a low likelihood of direct cardiac ion channel interactions. This characteristic supports waiving the requirement for thorough QT assessment for products comprised of naturally occurring amino acids unless proarrhythmia potential is suggested by nonclinical or clinical data.<\/jats:p>","DOI":"10.1002\/cpt.3047","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T10:20:06Z","timestamp":1694600406000},"page":"1332-1341","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["ICH S7B <i>In Vitro<\/i> Assays Do Not Address Mechanisms of QT<sub>C<\/sub> Prolongation for Peptides and Proteins \u2013 Data in Support of Not Needing Dedicated QT<sub>C<\/sub> Studies"],"prefix":"10.1002","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-4840","authenticated-orcid":false,"given":"Wendy W.","family":"Wu","sequence":"first","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research US\u00a0Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Choe","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research US\u00a0Food and Drug Administration  Silver Spring Maryland USA"},{"name":"Division of Hematology, Oncology, Toxicology, Office of Oncologic Diseases, Office of New Drugs, Center for Drug Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Johannesen","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Nephrology, Office of Cardiology, Hematology, Endocrinology and Nephrology, Office of New Drugs, Center for Drug Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-1205","authenticated-orcid":false,"given":"Jose","family":"Vicente","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Nephrology, Office of Cardiology, Hematology, Endocrinology and Nephrology, Office of New Drugs, Center for Drug Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Bende","sequence":"additional","affiliation":[{"name":"Division of Cardiometabolic and Endocrine Pharmacology, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"},{"name":"Takeda Pharmaceutical Company Limited  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman L.","family":"Stockbridge","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Nephrology, Office of Cardiology, Hematology, Endocrinology and Nephrology, Office of New Drugs, Center for Drug Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-3297","authenticated-orcid":false,"given":"David G.","family":"Strauss","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research US\u00a0Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Garnett","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Nephrology, Office of Cardiology, Hematology, Endocrinology and Nephrology, Office of New Drugs, Center for Drug Evaluation and Research US Food and Drug Administration  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10]]},"reference":[{"key":"e_1_2_13_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(02)00846-5"},{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00395.x"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2010.08.008"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14101"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfx125"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfu198"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2272-7_3"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/tx800035b"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01572"},{"key":"e_1_2_13_10_1","first-page":"1324","article-title":"Use\u2010dependent 'agonist' effect of azimilide on the HERG channel","volume":"291","author":"Jiang M.","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.200308812"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3495(03)70028-9"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200460200"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1113\/JP272151"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2008.04.001"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202337"},{"key":"e_1_2_13_17_1","unstructured":"Anonymous.ICH E14 Q&As (R3): The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non\u2010Antiarrhythmic Drugs.(2015)."},{"key":"e_1_2_13_18_1","unstructured":"Anonymous.ICH S6(R1): Preclinical safety evaluation of biotechnology\u2010derived pharmaceuticals.(2011)."},{"key":"e_1_2_13_19_1","unstructured":"Anonymous.Definition of the term \u201cBiological Product\u201d.10057\u201063 (Federal Register 02\/21\/2020) (2020)."},{"key":"e_1_2_13_20_1","unstructured":"Anonymous.ICH E14\/S7B IWG: Questions and Answers: Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential.(2022)."},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004667"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.06.005"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.2010.06246.x"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0016-z"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00813743"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.2000.279.6.R2022"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00039"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-817728-0.00003-6"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)03423-9"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aes158"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.102"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2015.00026"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C400025200"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208321"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/27.3.525"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2007.09.004"},{"key":"e_1_2_13_37_1","first-page":"I17","article-title":"Modulation of calcium channel function by phosphorylation in Guinea pig ventricular cells and phospholipid bilayer membranes","volume":"61","author":"Trautwein W.","year":"1987","journal-title":"Circ. Res."},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.2001.280.3.H1075"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(00)00516-9"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000044941.13346.74"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.07.001"},{"key":"e_1_2_13_42_1","first-page":"YE01","article-title":"Requirements for minimum sample size for sensitivity and specificity analysis","volume":"10","author":"Bujang M.A.","year":"2016","journal-title":"J. Clin. Diagn. Res."},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00319"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T15:09:50Z","timestamp":1700147390000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/cpt.3047"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3047","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"2023-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}